Thiotepa

Drug Profile

Thiotepa

Alternative Names: Tepadina; Thioplex

Latest Information Update: 11 Mar 2015

Price : $50

At a glance

  • Originator ADIENNE
  • Class Antineoplastics; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haematological disorders; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Feb 2015 Thiotepa licensed to LINK Healthcare in Australia and New Zealand
  • 01 Jan 2015 Adienne initiates enrolment in a phase IV pharmacokinetics trial (In children, In adolescents) for Haematological disorders in Italy (EudraCT2014-004371-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top